| Professor Andrew D Morris
am the Professor of Diabetic Medicine and Director of the Biomedical
Research Institute at the University of Dundee. I lead a translational
research team that focuses on the epidemiological and molecular
aetiological basis of diabetes and its complications. I also have a
major interest in how managed clinical networks can improve patient
care across geographical boundaries. I lead the internationally
acclaimed DARTS research study, have published over 200 original papers
and have attracted over £20million in peer reviewed grant funding. I am
the principal investigator on many clinical studies of new therapeutics
of diabetes as well as genetics of diabetes, including the Wellcome
Trust United Kingdom Case Control Collection for Type 2 Diabetes that
is recruiting 15,000 individuals. I am also the principal investigator
of Generation Scotland, a study of the genetic health in 50,000 Scots.
I was awarded the RD Lawrence Award by Diabetes UK in 2003, the Saltire
Society Scottish Science Award in 2005 and am a Fellow of the Royal
Society of Edinburgh, Scotland’s national academy of science and
letters, and Fellow of the Academy of Medical Sciences. I was appointed
by the Minister for Health and Community Care to be Lead Clinician for
diabetes in Scotland (2002-2006) and led a national programme of
quality improvement in diabetes care. I also chair the Translational
Medicine Research Collaboration Steering Group, a unique £50million
collaboration between all Medical Schools in Scotland and the
pharmaceutical company Wyeth.
5 Key Papers:
Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, Hattersley AT,McCarthy MI, Morris AD,
Palmer CN, Pearson ER. Reduced-function SLC22A1polymorphisms encoding
organic cation transporter 1 and glycemic response tometformin: a
GoDARTS study. Diabetes. 2009 58:1434-9.
Timpson NJ, Lindgren CM, Weedon MN, Randall J, Ouwehand WH, Strachan DP,Rayner NW, Walker M, Hitman GA, Doney AS, Palmer CN, Morris AD,
Hattersley AT,Zeggini E, Frayling TM, McCarthy MI. Adiposity-related
heterogeneity in patterns of type 2 diabetes susceptibility observed in
genome-wide association data. Diabetes. 2009;58:505-10.
Sandhu MS, Weedon
MN, Fawcett KA, Wasson J, Debenham SL, Daly A, Lango H,Frayling TM,
Neumann RJ, Sherva R, Blech I, Pharoah PD, Palmer CN, Kimber C,
Tavendale R, Morris AD, McCarthy MI, Walker M, Hitman
G, Glaser B, Permutt MA, Hattersley AT, Wareham NJ, Barroso I. Common
variants in WFS1 confer risk of type 2 diabetes. Nat Genet.
Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, Hattersley AT, Morris AD,
Palmer CN. Variation in TCF7L2 influences therapeutic response to
sulfonylureas: a GoDARTs study. Diabetes. 2007 Aug;56:2178-82.
TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry
JR, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC,
Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lawlor DA,
Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D,
Ferrucci L, Loos RJ, Barroso I, Wareham NJ, Karpe F, Owen KR, Cardon
LR, Walker M, Hitman GA, Palmer CN, Doney AS, Morris AD,
Smith GD, Hattersley AT, McCarthy MI. A common variant in the FTO gene
is associated with body mass index and redisposes to childhood and
adult obesity. Science. 2007;316:889-94.